Teon Therapeutics, Inc.

Teon Therapeutics is a private biopharma start-up developing a portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that is superior to other candidates like AB928 and AZD4635, and will enter Phase 1b trials in 2021. Our experienced leadership team are experts in adenosine and GPCR therapeutics and were primary inventors of Lexiscan and Ranexa, which led to the acquisition of CV Therapeutics by Gilead for $1.4B. We are currently raising a Series A that will help achieve multiple clinical milestones in the next 24 months.

Overview presentation here:
https://teonthera.egnyte.com/dl/MpAMqy0i5n